
Opinion|Videos|September 11, 2024
Understanding Oligometastatic Disease in Prostate Cancer: Insights from PSMA PET Imaging
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Key opinion leaders examine the role of advanced imaging agents, particularly PSMA PET and other radiotracers, in identifying and defining oligometastatic disease in patients with prostate cancer.
Advertisement
Video content above is prompted by the following:
- How do imaging agents, such as PSMA PET or other radiotracers, contribute to the detection and characterization of oligometastasis in prostate cancer patients?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears Updated AI Mammography Software for Breast Arterial Calcification Detection
2
Could Risk-Stratified MRI Surveillance Supplant Semiannual Ultrasound Exams in Patients with Cirrhosis?
3
FDA Approves New Tau PET Imaging Agent for Alzheimer’s Disease
4
Perspectives on Peer Review, Medicolegal Cases and Judgment in Radiology
5










